Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study ...
Researchers at Children's Hospital of Philadelphia (CHOP) reported long-term clinical outcomes for the largest single center cohort of individuals who underwent complex reconstructive surgery for ...
Receiving a complex prenatal diagnosis can quickly turn an exciting pregnancy into a whirlwind of medical choices, emotional stress and legal questions. A prominent dispute reported by ABC7 Los ...
Rumi is now recuperating under the loving care of his parents,” Nausheen Gilkar and Omar Ahmed’s attorney said in a statement ...
The complex Norwood procedure performed this week is the first step in a multi-stage surgical process expected to stretch ...
Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular eje ...
Senate Finance advanced Chris Klomp for HHS deputy secretary by a vote of 15 to 12, sending him to a full Senate vote. What the No. 2 post means for families. A draft federal plan would end weekly ...
Children's Hospital Colorado (Children's Colorado) successfully performed the hospital's first-ever heart and liver dual organ transplant, with support from dozens of team members across 25 different ...
Longeveron, the US biotech developing cellular therapies for rare pediatric and aging-related conditions, saw its shares fall around 59% on Thursday after it reported that its Phase IIb ELPIS II trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results